All In Biotech

Drug Trial Radar · NCT05396105

Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema

A Phase II/III, Extension Study of Orally Administered PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema

Last checked: Nov 19, 2026Latest source record: Jul 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitationPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Enrolling by invitation

Enrollment

150

Planned (sponsor's estimate)

Start

Dec 28, 2022

Primary completion

Jun 2027

Study completion Jun 2027

Sponsor

Lead sponsor
Pharvaris Netherlands B.V.Industry
Sponsor type
Industry
First posted
May 31, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluates the safety and efficacy of long-term on-demand treatment with orally administered deucrictibant for acute hereditary angioedema (HAE) attacks, including laryngeal attacks. The study will enroll participants from Study PHA022121-C201 (NCT04618211), Study PHA022121-C306 (NCT06343779) and deucrictibant treatment naïve HAE-nC1INH adult participants who elect to participate in this extension study and meet the eligibility requirements.

Conditions

  • Hereditary Angioedema
  • Hereditary Angioedema Type I
  • Hereditary Angioedema Type II
  • Hereditary Angioedema Types I and II
  • Hereditary Angioedema Attack
  • Hereditary Angioedema With C1 Esterase Inhibitor Deficiency
  • Hereditary Angioedema - Type 1
  • Hereditary Angioedema - Type 2
  • Hereditary Angioedema - Type 3
  • C1 Esterase Inhibitor [C1-INH] Deficiency
  • C1 Esterase Inhibitor Deficiency
  • C1 Esterase Inhibitor, Deficiency of
  • C1 Inhibitor Deficiency
  • Hereditary Angioedema Type III
  • Hereditary Angioedema (HAE)
  • Hereditary Angioedema Type I and II
  • HAE With Normal C1 Esterase Inhibitor

Interventions

  • deucrictibantDrug

    3 capsules of deucrictibant or matching placebo will be administered orally for each HAE attack

  • deucrictibantDrug

    deucrictibant soft capsules will be administered orally for each HAE attack

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment-emergent Adverse Events (TEAEs), treatment-related TEAEs, treatment-emergent serious adverse events (TESAEs), treatment-related TESAEs, and TEAEs leading to deucrictibant discontinuationTime frame: From enrollment through study completion, up to 54 months (dependent on time of enrollment).
  2. Heart RateTime frame: From enrollment through study completion, up to 54 months (dependent on time of enrollment).
  3. Blood pressureTime frame: From enrollment through study completion, up to 54 months (dependent on time of enrollment).
  4. Body temperatureTime frame: From enrollment through study completion, up to 54 months (dependent on time of enrollment).
  5. Clinical laboratory testsTime frame: From enrollment through study completion, up to 54 months (dependent on time of enrollment).
  6. ElectrocardiogramsTime frame: From enrollment through study completion, up to 54 months (dependent on time of enrollment).
  7. Physical ExaminationTime frame: From enrollment through study completion, up to 54 months (dependent on time of enrollment).

Locations

60 sites in 24 countries. Site status is shown where the registry gives one.

  • Study site

    Birmingham, Alabama

  • Study site

    Little Rock, Arkansas

  • Study site

    San Diego, California

  • Study site

    Santa Monica, California

  • Study site

    Walnut Creek, California

  • Study site

    Colorado Springs, Colorado

  • Study site

    Chevy Chase, Maryland

  • Study site

    Boston, Massachusetts

  • Study site

    Detroit, Michigan

  • Study site

    St Louis, Missouri

  • Study site

    Hershey, Pennsylvania

  • Study site

    Dallas, Texas

  • Study site

    Buenos Aires, Argentina

  • Study site

    Salta, Argentina

  • Study site

    Campbelltown, New South Wales, Australia

  • Study site

    Graz, Austria

  • Study site

    Vienna, Austria

  • Study site

    Ribeirão Preto, Brazil

  • Study site

    Santo André, Brazil

  • Study site

    São Paulo, Brazil

  • Study site

    Salvador, Estado de Bahia, Brazil

  • Study site

    Sofia, Bulgaria

  • Study site

    Sofia, Bulgaria

  • Study site

    Edmonton, Alberta, Canada

  • Study site

    Montreal, Quebec, Canada

  • Study site

    Brno, Czechia

  • Study site

    Grenoble, France

  • Study site

    Paris, France

  • Study site

    Berlin, Germany

  • Study site

    Frankfurt am Main, Germany

  • Study site

    Frankfurt am Main, Germany

  • Study site

    Lübeck, Germany

  • Study site

    Hong Kong, Hong Kong

  • Study site

    Budapest, Hungary

  • Study site

    Ashkelon, Israel

  • Study site

    Catania, Italy

  • Study site

    Milan, Italy

  • Study site

    Milan, Italy

  • Study site

    Naples, Italy

  • Study site

    Padova, Italy

Showing 40 of 60 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.